Contact
searchSearch
HMP Global

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

August 2013 - FRMC

Foam Approved for Acne Vulgaris - Fabior™ (tazarotene) Foam, 0.1%
08/15/2013
The FDA approved tazarotene foam for acne vulgaris based on the results of two, phase 3 studies conducted in the US and Canada. 
The FDA approved tazarotene foam for acne vulgaris based on the results of two, phase 3 studies conducted in the US and Canada. 
The FDA approved tazarotene foam...
08/15/2013
First Report Managed Care
Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia
08/15/2013
Chicago—Of patients with chronic myeloid leukemia (CML) who are treated with tyrosine-kinase inhibitors (TKIs), 20% to 30% develop resistance to the drugs; others are intolerant.
Chicago—Of patients with chronic myeloid leukemia (CML) who are treated with tyrosine-kinase inhibitors (TKIs), 20% to 30% develop resistance to the drugs; others are intolerant.
Chicago—Of patients with chronic...
08/15/2013
First Report Managed Care
Nivolumab to Treat Advanced Melanoma
08/15/2013
Chicago—After 2 years of treatment, 43% of patients with advanced melanoma who received nivolumab were alive, according to a phase 1 study. The 1-year overall survival rate was 62%, and median overall survival was 16.8 months. All patients...
Chicago—After 2 years of treatment, 43% of patients with advanced melanoma who received nivolumab were alive, according to a phase 1 study. The 1-year overall survival rate was 62%, and median overall survival was 16.8 months. All patients...
Chicago—After 2 years of...
08/15/2013
First Report Managed Care
Patient-Reported Outcomes in Patients with Multiple Myeloma
08/15/2013
Chicago—A broad perspective of disease burden and impact of treatment may be gained utilizing patient-reported outcomes (PROs) such as health-related quality of life (HRQoL). For patients with multiple myeloma (MM) and other hematologic...
Chicago—A broad perspective of disease burden and impact of treatment may be gained utilizing patient-reported outcomes (PROs) such as health-related quality of life (HRQoL). For patients with multiple myeloma (MM) and other hematologic...
Chicago—A broad perspective of...
08/15/2013
First Report Managed Care
Lenvatinib for Advanced BRAF Wild-Type Melanoma
08/15/2013
Chicago—At a minimum of 15 months follow-up, patients with unresectable, metastatic BRAF wild-type melanoma who received 24 mg of lenvatinib once daily had a median progression-free survival of 3.7 months and a median overall survival of 9.5...
Chicago—At a minimum of 15 months follow-up, patients with unresectable, metastatic BRAF wild-type melanoma who received 24 mg of lenvatinib once daily had a median progression-free survival of 3.7 months and a median overall survival of 9.5...
Chicago—At a minimum of 15...
08/15/2013
First Report Managed Care
Survey on Oncology Drug Shortages
08/15/2013
Chicago—According to a survey, most oncologists and hematologists have faced drug shortages in recent years and have had to deny, delay, or modify treatment regimens for cancer patients. Although the scarcity of these drugs has received...
Chicago—According to a survey, most oncologists and hematologists have faced drug shortages in recent years and have had to deny, delay, or modify treatment regimens for cancer patients. Although the scarcity of these drugs has received...
Chicago—According to a survey,...
08/15/2013
First Report Managed Care
Butrans® (buprenorphine) Transdermal System and Chronic Low Back Pain
08/15/2013
Patients with moderate-to-severe chronic low back pain who received 12 weeks of treatment with the Butrans® (buprenorphine) transdermal system had significant improvements in several activities of daily living compared with a placebo group.
Patients with moderate-to-severe chronic low back pain who received 12 weeks of treatment with the Butrans® (buprenorphine) transdermal system had significant improvements in several activities of daily living compared with a placebo group.
Patients with moderate-to-severe...
08/15/2013
First Report Managed Care
Opioid Usage and Diabetic Peripheral Neuropathy
08/15/2013
An analysis of a claims database found that 61% of patients with diabetic peripheral neuropathy had not received treatment for the disease.Although if patients took medications, they typically used opioids to manage the condition.
An analysis of a claims database found that 61% of patients with diabetic peripheral neuropathy had not received treatment for the disease.Although if patients took medications, they typically used opioids to manage the condition.
An analysis of a claims database...
08/15/2013
First Report Managed Care
Linaclotide for Treatment of IBS-C and Chronic Constipation
08/15/2013
There are limited options available for the treatment of irritable bowel syndrome with constipation, but linaclotide has recently been approved.
There are limited options available for the treatment of irritable bowel syndrome with constipation, but linaclotide has recently been approved.
There are limited options...
08/15/2013
First Report Managed Care

Department

Conference Insider
Value-Based Healthcare
08/15/2013
Fort Lauderdale—In the United States, approximately 100 million adults have chronic pain, which is associated with $275 billion in healthcare costs and $300 billion in lost worker productivity each year. The combined costs are larger than...
Fort Lauderdale—In the United States, approximately 100 million adults have chronic pain, which is associated with $275 billion in healthcare costs and $300 billion in lost worker productivity each year. The combined costs are larger than...
Fort Lauderdale—In the United...
08/15/2013
First Report Managed Care

Advertisement

Advertisement

Advertisement

FRMC Volume 21, Issue 3

Current Issue

September 2024
Volume 21
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

What's Trending?

News
Teva Receives FDA Approval for First Generic Lexapro
03/14/2012
The US Food and Drug Administration (FDA) granted the first generic Lexapro (escitalopram tablets) approval to treat adults with depression and generalized anxiety disorder. The drug, manufactured by Teva Pharmaceutical Industries, will come...
The US Food and Drug Administration (FDA) granted the first generic Lexapro (escitalopram tablets) approval to treat adults with depression and generalized anxiety disorder. The drug, manufactured by Teva Pharmaceutical Industries, will come...
The US Food and Drug...
03/14/2012
First Report Managed Care
News Connection
Poor Depression Care After Heart Attack, Stroke Increases Patient Costs
11/20/2019
Inadequate management of a patient’s depression following heart attack or stroke is linked with notably higher health care costs, according to a study published online in the Journal of Medical Economics. 
Inadequate management of a patient’s depression following heart attack or stroke is linked with notably higher health care costs, according to a study published online in the Journal of Medical Economics. 
Inadequate management of a...
11/20/2019
First Report Managed Care
News
Over-the-Counter Insulin Available for Patients with Diabetes Who Cannot Afford Prescription
01/07/2016
Although it is uncommon, patients with diabetes can legally purchase specific forms of insulin without a prescription, something many physicians are not even aware of.  
Although it is uncommon, patients with diabetes can legally purchase specific forms of insulin without a prescription, something many physicians are not even aware of.  
Although it is uncommon,...
01/07/2016
First Report Managed Care
News
Few Medicare Providers Offer Intensive Behavioral Therapy for Obesity
10/23/2023
Just 1% of primary care providers who cared for Medicare beneficiaries provided intensive behavioral therapy (IBT) for obesity at any time between 2013 and 2019, according to a study published online in PLOS One.
Just 1% of primary care providers who cared for Medicare beneficiaries provided intensive behavioral therapy (IBT) for obesity at any time between 2013 and 2019, according to a study published online in PLOS One.
Just 1% of primary care...
10/23/2023
First Report Managed Care
Feature
Efficacy and Safety of Nilotinib Compared with Imatinib in Patients with Chronic Myeloid Leukemia
01/28/2010
New Orleans—During a late breaking abstract session at the ASH conference, Giuseppe Saglio of the University of Turin, San Luigi Hospital, Orbassano, Italy, presented results of the ENESTnd (Evaluating Nilotinib Efficacy and Safety in...
New Orleans—During a late breaking abstract session at the ASH conference, Giuseppe Saglio of the University of Turin, San Luigi Hospital, Orbassano, Italy, presented results of the ENESTnd (Evaluating Nilotinib Efficacy and Safety in...
New Orleans—During a late...
01/28/2010
First Report Managed Care

Video Insights

Videos
Bridging the Gaps in Prior Authorization: Challenges, Solutions, and Collaboration for Better Patient Care
11/13/2024
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
David Sand, MD, MBA, chief...
11/13/2024
First Report Managed Care
Richard Lipton, MD
Videos
The Evolving Role of CGRP-targeting Therapies in Migraine Prevention
10/31/2024
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides...
10/31/2024
First Report Managed Care
Alexander Spira, MD, PhD
Videos
Unmet Needs in the Treatment and Management of Non–Small Cell Lung Cancer
09/26/2024
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD,...
09/26/2024
First Report Managed Care
Videos
Treatment Options for NSCLC: A Discussion on Coverage, Clinical Outcomes, and Payer Perspectives
09/25/2024
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research...
09/25/2024
First Report Managed Care
Title Card
Videos
Addressing the Root Cause of a Common Ocular Condition: A Virtual Roundtable
09/04/2024
View a roundtable discussion on Demodex blepharitis, a prevalent ocular condition that often goes undiagnosed in patients.
View a roundtable discussion on Demodex blepharitis, a prevalent ocular condition that often goes undiagnosed in patients.
View a roundtable discussion on...
09/04/2024
First Report Managed Care
Jordan Bazinsky
Videos
Addressing Health Disparities and Promoting Equity: The Role of Advanced Imaging Solutions
08/15/2024
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...
Guest expert Jordan Bazinsky...
08/15/2024
First Report Managed Care
Farrukh Awan, MD
Videos
Promising Therapies and Clinical Trials for Chronic Lymphocytic Leukemia
08/14/2024
Farrukh Awan, MD, highlights promising therapies and clinical trials within the field of chronic lymphocytic leukemia (CLL).
Farrukh Awan, MD, highlights promising therapies and clinical trials within the field of chronic lymphocytic leukemia (CLL).
Farrukh Awan, MD, highlights...
08/14/2024
Journal of Clinical Pathways
Hayward
Videos
Evolving Health Care Contact Centers Into Drivers of Value-Based Care
07/31/2024
Discover how health care contact centers can transform into drivers of value-based care through AI, automation, upskilling agents, and rethinking workflows and metrics to improve patient outcomes and population health.
Discover how health care contact centers can transform into drivers of value-based care through AI, automation, upskilling agents, and rethinking workflows and metrics to improve patient outcomes and population health.
Discover how health care contact...
07/31/2024
First Report Managed Care
Lucille Accetta Headshot
Videos
Enhancing Patient Medication Adherence: Insights and Strategies From Asembia 2024
06/11/2024
Lucille Accetta, PharmD, MBA, MSPH, Senior Vice President of CVS Specialty Operations
Key stakeholders in the health care industry gathered to discuss prevalent topics at this year's Asembia annual summit. Medication adherence emerged as one of the most talked-about issues. In a session led by Lucille Accetta, PharmD, MBA,...
Key stakeholders in the health care industry gathered to discuss prevalent topics at this year's Asembia annual summit. Medication adherence emerged as one of the most talked-about issues. In a session led by Lucille Accetta, PharmD, MBA,...
Key stakeholders in the health...
06/11/2024
First Report Managed Care
Melissa Andel, Principal, CommonHealth Solutions, LLC
Videos
Navigating the Impact of the Inflation Reduction Act: Implications for Payers, Patients, and Manufacturers
05/24/2024
Melissa Andel, Principal, CommonHealth Solutions, LLC
Learn about the impacts of the Inflation Reduction Act on payers and patients, highlighting the changes in Medicare benefits and drug coverage coming in 2025 and 2026.
Learn about the impacts of the Inflation Reduction Act on payers and patients, highlighting the changes in Medicare benefits and drug coverage coming in 2025 and 2026.
Learn about the impacts of the...
05/24/2024
First Report Managed Care

Subscribe to our eNewsletters!

First Report Managed Care Newsletter

August 2013 Volume 10 Issue 8

View Issue Archive
Editorial Correspondence

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement